文献速递临床试验与 GCP流行病学与生物统计

急性心肌梗死后幽门螺杆菌筛查:HELP-MI SWEDEHEART集群随机交叉试验

Helicobacter pylori Screening After Acute Myocardial Infarction: The Cluster Randomized Crossover HELP-MI SWEDEHEART Trial.
PubMed 文献 · JAMA · 2025-01-01

这项全国性、开放标签、两期两序列的集群随机交叉临床试验在瑞典35家医院18个集群中开展,评估急性心肌梗死住院期间常规幽门螺杆菌筛查能否减少上消化道出血。共随访18466例患者,筛查期9245例与非筛查期9221例,中位随访1.9年后主要终点上消化道出血发生率比为0.90(95%CI 0.77-1.05;P=0.18),常规筛查未显著降低上消化道出血风险。

要点

  • 急性心肌梗死患者常规幽门螺杆菌筛查未显著降低上消化道出血风险(RR 0.90;95%CI 0.77-1.05;P=0.18)。
  • 筛查期6480例(70%)接受检测,其中1532例(23.6%)幽门螺杆菌阳性。
  • 预设非多重校正亚组分析显示干预效应存在异质性,交互作用P=0.03。

核心结论

  • 在未选择的急性心肌梗死患者中,常规幽门螺杆菌筛查未显著降低上消化道出血风险。

研究设计与样本

  • 全国性、开放标签、两期、两序列、集群随机交叉临床试验,利用临床注册登记定义研究人群并收集数据,并与瑞典国家健康数据登记库合并。
  • 2021年11月17日至2024年1月17日,35家瑞典医院分为18个集群,随机分配至先进行1年常规幽门螺杆菌筛查再经2个月洗脱期交叉至1年常规护理,或反之。
  • 筛查期为所有因心肌梗死住院的患者在标准护理基础上常规增加尿素呼气试验筛查幽门螺杆菌。
  • 共随访18466例心肌梗死患者(中位年龄71岁[IQR 61-79],男性13138例[71%]),筛查期9245例,非筛查期9221例,随访至2025年1月17日。

主要发现

  • 筛查期2284例(24.7%)与非筛查期2275例(24.7%)入院时报告使用质子泵抑制剂。
  • 筛查期6480例(70%)接受检测,其中1532例(23.6%)幽门螺杆菌阳性。
  • 中位随访1.9年后,筛查组299例发生主要终点上消化道出血(发生率16.8事件/1000人年;3年累积风险4.1%),常规护理组336例(发生率19.2事件/1000人年;3年累积风险4.6%)(率比[RR] 0.90;95%CI 0.77-1.05;P=0.18)。
  • 预设非多重校正亚组分析显示干预效应存在异质性:无贫血RR 0.98(95%CI 0.80-1.21),轻度贫血RR 0.64(95%CI 0.42-0.98),中度至重度贫血RR 0.44(95%CI 0.23-0.87),交互作用P=0.03。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Upper gastrointestinal bleeding is common after myocardial infarction. OBJECTIVE: To determine whether routine screening for Helicobacter pylori infection during hospitalization for myocardial infarction reduces bleeding events and improves clinical outcomes. DESIGN, SETTING, AND PARTICIPANTS: A nationwide, open-label, 2-period, 2-sequence, cluster randomized, crossover clinical trial using a clinical registry for study population definition and data collection merged with national Swedish health data registries. From November 17, 2021, through January 17, 2024, thirty-five Swedish hospitals grouped into 18 clusters were randomized to a sequence of 1 year with routine H pylori screening of all patients with acute myocardial infarction followed by a washout period of 2 months before crossing over to 1 year with usual care or vice versa. Patients were followed up until January 17, 2025. INTERVENTION: Routine addition of H pylori screening by urea breath test to standard care in all patients hospitalized for myocardial infarction during the screening periods. MAIN OUTCOME AND MEASURE: Upper gastrointestinal bleeding, analyzed by a negative binomial model in the intention-to-treat population. RESULTS: A total of 18 466 patients (median age, 71 years [IQR, 61-79], 13 138 males [71%]) with myocardial infarction were followed up: 9245 during the screening periods and 9221 during the nonscreening periods. At admission, 2284 during the screening periods and 2275 during the nonscreening periods (both 24.7%) reported proton pump inhibitor use. During screening periods, 6480 patients (70%) had undergone testing, of those 1532 (23.6%) tested positive for H pylori. After a median follow-up of 1.9 years, 299 patients in the screening group (incidence rate, 16.8 events per 1000 person-years; cumulative hazard at 3 years, 4.1%) and 336 in the usual care group (incidence rate, 19.2 events per 1000 person-years; cumulative hazard at 3 years, 4.6%) experienced the primary end point of upper gastrointestinal bleeding (rate ratio [RR], 0.90; 95% CI, 0.77-1.05; P = .18). Predefined nonmultiplicity adjusted subgroup analyses showed a heterogeneous intervention effect; for no anemia (RR, 0.98; 95% CI, 0.80-1.21), mild anemia (RR, 0.64; 95% CI, 0.42-0.98), and moderate to severe anemia (RR, 0.44; 95% CI, 0.23-0.87; P for interaction = .03). CONCLUSIONS AND RELEVANCE: Among unselected patients with acute myocardial infarction, routine H pylori screening did not significantly reduce the risk of upper gastrointestinal bleeding. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05024864.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Hofmann R, James S, Sundqvist MO, et al. Helicobacter pylori Screening After Acute Myocardial Infarction: The Cluster Randomized Crossover HELP-MI SWEDEHEART Trial. JAMA. 2025. PMID: 40887995. doi:10.1001/jama.2025.15047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。